Zobrazeno 41 - 50
of 819
pro vyhledávání: ''
Autor:
Masaya Hiyoshi, Kensuke Otani, Keisuke Hata, Kazushige Kawai, Yasutaka Shuno, Kazuhiro Ishimaru, Kei Muro, Toshiaki Tanaka, Soichiro Ishihara, Kazuhito Sasaki, Hiroaki Nozawa, Koji Murono, Hiroshi Nagata, Takeshi Nishikawa, Shigenobu Emoto, Manabu Kaneko
Publikováno v:
Cancer Chemotherapy and Pharmacology. 83:145-150
Peritoneal carcinomatosis of colorectal cancer origin is associated with poor prognosis. With regard to ovarian, gastric, and pancreatic cancer, the safety and efficacy of intraperitoneal administration of paclitaxel (ip PTX) has been demonstrated. T
Autor:
Hitoshi Ando, Hiroya Taniguchi, Shoji Fukushima, Masaki Kajita, Masahiro Aoki, Shigenori Kadowaki, Ayako Hasegawa, Akimitsu Maeda, Masahiro Tajika, Kazuhide Inaguma, Akio Fujimura, Kei Muro, Kei Irie
Publikováno v:
Cancer Chemotherapy and Pharmacology. 83:107-113
The ability of predicting severe adverse reactions caused by regorafenib is important. We evaluated regorafenib concentrations for adverse reaction risks and assessed the relevance of laboratory values and gene polymorphisms. A total of 28 Japanese c
Autor:
Laura Visa, Ana Reig, Laureano Fernández-Cruz, Xabier García-Albéniz, Josep Antoni Bombí, Luis Sabater, Juan Ramón Ayuso, Santiago Sánchez-Cabús, Berta Laquente, Ignacio Povés, Carles Conill, Joan Fabregat, Lydia Gaba, Carlos Valls, Roberto Díaz-Beveridge, Angels Ginès, María Cambray, Marta Martin-Richard, Javier Rodríguez, Joan Maurel, Antonio Ferrández, Susana Roselló
Publikováno v:
CANCER CHEMOTHERAPY AND PHARMACOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
BackgroundNeoadjuvant therapy (NAT) for pancreatic adenocarcinoma (PDAC) patients has shown promising results in non-randomized trials. This is a multi-institutional phase II trial of NAT in resectable PDAC patients.MethodsPatients with confirmed res
Autor:
Yoshiki Murakami, Hiroyasu Morikawa, Akihiro Tamori, Masaru Enomoto, Yuga Teranishi, Ayako Iida-Ueno, Le Thi Thanh Thuy, Atsushi Hagihara, Norifumi Kawada, Sawako Uchida-Kobayashi, Hideki Fujii
Publikováno v:
Cancer Chemotherapy and Pharmacology. 82:857-864
This study aimed to identify a biomarker for predicting the response to sorafenib in patients with hepatocellular carcinoma (HCC). Of 100 patients with unresectable HCC who received sorafenib treatment in our institute (Cohort A), 48 had stored plasm
Autor:
Sayaka Arisaka, Toshiaki Kadokura, Itaru Endo, Ryusei Matsuyama, Koki Goto, Takafumi Kumamoto, Ryutaro Mori, Masataka Taguri, Yusuke Suwa, Mari Sato
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose To assess the predictive ability of the maximum chemiluminescence intensity (CImax) for severe neutropenia (SN) during neoadjuvant chemo(radio)therapy [NAC(RT)] in patients with advanced pancreatic or biliary tract cancer. Methods Clinicopath
Autor:
Mustafa Karaagac, Ali Murat Tatli, Mustafa Ozdogan, Ali Ayberk Besen, Ahmet Bilici, Sema Sezgin Goksu, Mustafa Atcı, Muhammet Ali Kaplan, Senar Ebinç, Mukremin Uysal, Sabin Göktaş Aydın, Hasan Şenol Coşkun, Mehmet Artac, Caglayan Geredeli, Huseyin Mertsoylu
Publikováno v:
Cancer chemotherapy and pharmacology. 88(5)
Purpose In this study, we looked for whether treatment-induced rash predicts treatment efficacy in patients with recurrent/metastatic HNSCC treated with Cetuximab and chemotherapy. Methods Patients who were treated with platinum-based chemotherapy an
Publikováno v:
Cancer chemotherapy and pharmacology. 87(5)
The aim of this study was to test whether CES1, UMPS, DPYS and TPYS polymorphisms influence the outcomes of gastroenteric cancer patients. We consecutively enrolled 338 patients who were diagnosed with colorectal and gastric cancer from January 2016
Publikováno v:
Cancer chemotherapy and pharmacology. 87(5)
Some cancer patients experience an increase in the leukocyte count, platelet count, and absolute neutrophil count compared to the baseline level after chemotherapy. We identify this phenomenon as "myelostimulation", which seems to go against the myel
Autor:
José Federico González González, Jaime Feliu, P. Vicente, Esther Casado Gonzalez, Guillermo Lopez-Vivanco, Ana Montes, Carmen Garcia Piernavieja, Teresa Macarulla, Irene Gonzalez Cebrian, A. Muñoz, Manuel Valladares-Ayerbes, Mónica Jorge Fernández, Juan Ignacio Delgado-Mingorance, Bartomeu Massuti, Ana Albero, Rebeca Mondéjar Solís, Guillermo Quintero-Aldana
Publikováno v:
CANCER CHEMOTHERAPY AND PHARMACOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Digital.CSIC. Repositorio Institucional del CSIC
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Digital.CSIC. Repositorio Institucional del CSIC
[Purpose] To evaluate the health-related quality of life (HRQoL), global health status (GHS), and deterioration-free survival of an elderly population (> 70 years) with unresectable locally advanced (LAPC) or metastatic pancreatic cancer (mPC) treate
Publikováno v:
Cancer chemotherapy and pharmacology. 86(3)
Cetuximab and panitumumab are monoclonal antibodies that target the epidermal growth factor receptor (EGFR). Treatment with cetuximab and panitumumab commonly causes hypomagnesemia, and optimal management of this adverse effect remains unclear. Here,